Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Objective: Nonalcoholic fatty liver disease can lead to hepatic inflammation/damage. Understanding the physiological mechanisms that contribute to excess hepatic lipid accumulation may help identify effective treatments. Design: We recruited 25 nondiabetic patients with severe obesity scheduled for bariatric surgery. To evaluate liver export of triglyceride fatty acids, we measured very-low-density lipoprotein (VLDL)–triglyceride secretion rates the day prior to surgery using an infusion of autologous [1-14C]triolein-labeled VLDL particles. Ketone body response to fasting and intrahepatic long-chain acylcarnitine concentrations were used as indices of hepatic fatty acid oxidation. We measured intraoperative hepatic uptake rates of plasma free fatty acids using a continuous infusion of [U-13C]palmitate, combined with a bolus dose of [9,10-3H]palmitate and carefully timed liver biopsies. Total intrahepatic lipids were measured in liver biopsy samples to determine fatty liver status. The hepatic concentrations and enrichment from [U-13C]palmitate in diacylglycerols, sphingolipids, and acyl-carnitines were measured using liquid chromatography/tandem mass spectrometry. Results: Among study participants with fatty liver disease, intrahepatic lipid was negatively correlated with VLDL-triglyceride secretion rates (r = −0.92, P = 0.01) but unrelated to hepatic free fatty acid uptake or indices of hepatic fatty acid oxidation. VLDL-triglyceride secretion rates were positively correlated with hepatic concentrations of saturated diacylglycerol (r = 0.46, P = 0.02) and sphingosine-1-phosphate (r = 0.44, P = 0.03). Conclusion: We conclude that in nondiabetic humans with severe obesity, excess intrahepatic lipid is associated with limited export of triglyceride in VLDL particles rather than increased uptake of systemic free fatty acids.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Votruba et al (90) that examine meal FA storage of females with obesity showed that meal FA is more efficient in visceral than in subcutaneous fat, except in those with large amounts of visceral fat; the efficiency of meal FA storage decreases as a function of visceral fat mass.”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [90]
In the citing paper
“In females with obesity given a mixed meal providing 40% REE, proportional meal fat storage is likewise greater in upper body subcutaneous fat than lower body subcutaneous fat and much greater than in visceral fat (90).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [90]
In the citing paper
“The same is not true in abdominal and femoral fat (90).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [90]
In the citing paper
“In general, the proportion of meal fat stored in upper body depots is the same or greater than that stored in the lower body (Table 3) (22, 88, 90).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [90]
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Sphingosine-1-phosphate: an enigmatic signalling lipid
Spiegel, S., & Milstien, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1103 · Cited by 2,075
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Cited by
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“This adaptation is, however, limited, as shown by studies indicating that VLDL secretion rates reach a plateau in mild to moderate steatosis and may even decrease upon progression to severe steatosis [52,83] and/or steatohepatitis [84,85].”
BackgroundMetabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Azzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Hepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
“Indeed, several findings in humans support this hypothesis: in patients with NASH the increase in VLDL secretion does not reach the extent of triglyceride synthesis (96) and in obese humans intrahepatic lipid was found to be negatively correlated with VLDL-triglyceride secretion rates (97).”
BackgroundLipid droplet contact sites in health and disease
Herker, E., Vieyres, G., Beller, M., Krahmer, N., & Bohnert, M. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.004 · Cited by 174
“In patients with non-alcoholic steatohepatitis (NASH), the increase in VLDL secretion does not reach the extent of TAG synthesis [93] and intrahepatic lipid levels are negatively correlated with VLDL-TAG secretion rates [94].”
BackgroundLipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 181
Saponaro, C., Sabatini, S., Gaggini, M., Carli, F., Rosso, C., Positano, V., Armandi, A., Caviglia, G. P., Faletti, R., Bugianesi, E., et al. (2022) · Liver International · doi:10.1111/liv.15377 · Cited by 116
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
“[83] described an inverse correlation between intrahepatic fat content and VLDL-TG secretion rate.”
BackgroundZhang, Z., Yuan, Y., Hu, L., Tang, J., Meng, Z., Dai, L., Gao, Y., Ma, S., Wang, X., Yuan, Y., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.006 · Cited by 102
Carpentier, A. C. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00620.2020 · Cited by 108
Hughey, C. C., Puchalska, P., & Crawford, P. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159209 · Cited by 58
Costa, D. N., Santosa, S., & Jensen, M. D. (2025) · Physiological Reviews · doi:10.1152/physrev.00008.2024 · Cited by 34
Self-citationEndpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 38
“However, this compensation usually cannot match the lipids overflowing the liver in these patients [79].”
BackgroundMetabolic role of the hepatic valine/3-hydroxyisobutyrate (3-HIB) pathway in fatty liver disease
Bjune, M. S., Lawrence‐Archer, L., Laupsa‐Borge, J., Sommersten, C. H., McCann, A., Glastad, R. C., Johnston, I. G., Kern, M., Blüher, M., Mellgren, G., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104569 · Cited by 37
“25,26 Conversion of pyruvate into acetyl-CoA represents a key regulatory step in hepatic lipid storage, largely determined by the pyruvate dehydrogenase kinase 4 (PDK4) which blocks the activity of the pyruvate dehydrogenase complex (PDC).”
BackgroundMoore, M. P., Shryack, G. E., Alessi, I. G., Wieschhaus, N., Meers, G. M.-E., Johnson, S. A., Wheeler, A. A., Ibdah, J. A., Parks, E. J., & Rector, R. S. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00336.2023 · Cited by 34
A Role for Fatty Acids in Peripheral Neuropathy Associated with Type 2 Diabetes and Prediabetes
Rumora, A. E., Kim, B., & Feldman, E. L. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0155 · Cited by 32
Crosstalk in extrahepatic and hepatic system in NAFLD / NASH
Duan, Y., Yang, Y. Z., Zhao, S., Bai, Y., Yao, W., Gao, X., & Yin, J. (2024) · Liver International · doi:10.1111/liv.15967 · Cited by 17
“24,88 Macrophage responses to different fatty acids vary; lauric and palmitic acids induce inflammatory mediators through TLR4 and NF-κ B pathways, whereas unsaturated fatty acids do not elicit such responses.”
InfluentialRamos-Román, M. A., Syed‐Abdul, M. M., Casey, B. M., Alger, J. R., Liu, Y., & Parks, E. J. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100288 · Cited by 17
“VLDL secretion may reduce liver-TG stores (44)”
ResultLiang, J., Shao, W., Ni, P., Liu, Q., Kong, W., Shen, W., Wang, Q., Huang, A., Zhang, G., Yang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202403442 · Cited by 19
Thilakarathna, W. P. D. W., & Rupasinghe, H. P. V. (2024) · Molecules · doi:10.3390/molecules29030709 · Cited by 12
“The VLDL secretion rate increases up to 5% of IHL accumulation, plateaus between 5–10%, and declines thereafter [66].”
BackgroundEl‐Ashmawy, N. E., Khedr, E. G., Al‐Ashmawy, G. M., & Kamel, A. A. (2024) · Nutrition · doi:10.1016/j.nut.2024.112517 · Cited by 8
Lytle, K. A., Bush, N. C., Triay, J. M., Kellogg, T. A., Kendrick, M. L., Swain, J. M., Gathaiya, N. W., Hames, K. C., & Jensen, M. D. (2021) · Obesity · doi:10.1002/oby.23149 · Cited by 6
“Protocol This study has previously been described in detail (7).”
BackgroundSelf-citationDumolt, J. H., Patel, M. S., & Rideout, T. C. (2020) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174420000239 · Cited by 6
Lytle, K. A., Chung, J. O., Bush, N. C., Triay, J., & Jensen, M. D. (2023) · Lipids · doi:10.1002/lipd.12367 · Cited by 9
Self-citationMisceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“…increased (and hypertriglyceridemia associated) [118, 134, 135], VLDL excretion is not sufficient to compensate for increased hepatic input [109, 120, 134] thus resulting in a net reduction of the lipid efflux capacity; this phenomenon is mediated by the combination of the mechanisms described…”
Syed‐Abdul, M. M., Moore, M. P., Wheeler, A. A., Ganga, R., Diaz‐Arias, A. A., Rector, R. S., Ibdah, J. A., & Parks, E. J. (2021) · AME Surgical Journal · doi:10.21037/asj-20-5 · Cited by 5
Yan, H., Li, X., Luo, W., Yuan, M., Liu, H., Tahir, R., Li, Q., Liu, Q., Song, K., Yang, S. Y., et al. (2025) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2025.108048 · Cited by 5
Kelty, T. J., Krause, A. A., & Rector, R. S. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2025 · Cited by 4
Rajan, S., Verano, M., Palaia, T. A., Prakashmurthy, C., Chung, J., Islam, S., Lee, L. J., James, A. W., Alemán, J. O., Goldberg, I. J., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101549 · Cited by 3
Zhang, F., Wang, Z., Zhang, H., & Zuo, Y.-Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696652 · Cited by 3
“This study provides human evidence that corroborates animal models demonstrating that hepatic steatosis alters systemic metabolic communication (28, 37).”
Contribution of de novo lipogenesis to the progression of nonalcoholic fatty liver disease
Abdul, M. M. S. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/81575 · Cited by 2
Sailis, A. B. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2026.2658739 · Cited by 1
“Hepatic steatosis increases triglyceride burden and shifts lipid handling toward enhanced very-low-density lipoprotein export, elevating circulating triglycerides and promoting ectopic lipid deposition in peripheral tissues (Hasan et al. 2019; Lytle et al. 2019).”
CORRECTION OF TRIACYLGLYCEROLS AND FREE FATTY ACIDS IN RAT BILE IN EXPERIMENTAL HEPATIC STEATOSIS
Томчук, В. А., Pototskyi, A., Gryshchenko, V., Veselskyi, S., & RESHETNIK, Y. (2022) · Ukrainian journal of veterinary sciences · doi:10.31548/ujvs.13(2).2022.53-62
Rôle des sphingolipides hépatiques dans la physiopathologie du diabète de type 2
Lachkar, F. (2022) · theses.fr (ABES) · doi:10.70675/2f1ce169zade5z47ccz96caz55bf77edab09
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Metadata
- Authors
- Lytle, K. A., Bush, N. C., Triay, J. M., Kellogg, T. A., Kendrick, M. L., Swain, J. M., Gathaiya, N. W., Hames, K. C., & Jensen, M. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Jensen, Michael D
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2019-08-13
- Volume
- 104
- Issue
- 12
- Pages
- 6171-6181
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6821207
- OpenAlex
- W2968560092
- Cited by
- 35
- References
- 44
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 4
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK40484, DK45343, DK50456)
- National Institutes of Health (UL1 RR24150, T32 DK07352)
- National Center for Advancing Translational Sciences (UL1 TR000135)
- American Diabetes Association (7-112-MN-36)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- non-alcoholic fatty liver disease, morbid obesity, hepatic lipid accumulation, VLDL triglyceride secretion, hepatic fatty acid oxidation, ketone bodies, long-chain acylcarnitines, diacylglycerol, sphingosine-1-phosphate, sphingolipids, hepatic lipolysis, bariatric surgery
- MeSH terms
- Adolescent, Adult, Fatty Acids, Fatty Acids, Nonesterified, Female, Humans, Lipoproteins, VLDL, Liver, Male, Middle Aged, Obesity, Morbid, Sphingolipids, Triglycerides, Bariatric Surgery, Lipid Metabolism, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.